Impact on replicative fitness of the G48E substitution in the protease of HIV-1: An in vitro and in silico evaluation

Journal of Acquired Immune Deficiency Syndromes

Volumn 48, Issue 3, 2008, Pages 255-262

  Zimmer, Jean Marie ^a   Roman, François ^a,e   Lambert, Christine ^a   Jonckheer, Abel ^b   Vazquez, Ana ^c   Plesséria, Jean Marc ^a   Servais, Jean Yves ^a   Covens, Kris ^d   Weber, Jan ^c   Van Laethem, Kristel ^d   Schmit, Jean Claude ^a   Vandamme, Anne Mieke ^d   Quinones Mateu, Miguel E ^c   De Maeyer, Marc ^b  

^a Retrovirology Laboratory   (Luxembourg)

^b Department of Chemistry   (Belgium)

^c LERNER RESEARCH INSTITUTE   (United States)

^d REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^e LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

Author keywords

HIV 1; Protease; Replicative capacity; Subtypes

Indexed keywords

ABACAVIR; AMPRENAVIR; DIDANOSINE; EFAVIRENZ; GAG PROTEIN; GLUTAMIC ACID; GLYCINE; GREEN FLUORESCENT PROTEIN; HYDROXYUREA; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; POL PROTEIN; PROTEINASE; RED FLUORESCENT PROTEIN; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE; PROTEINASE INHIBITOR;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; COMPARATIVE STUDY; COMPUTER MODEL; CONTROLLED STUDY; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; MOLECULAR DYNAMICS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVERTANT; SIMULATION; SITE DIRECTED MUTAGENESIS; VIROGENESIS; VIRUS REPLICATION; WILD TYPE; DRUG EFFECT; DRUG RESISTANCE; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUTATION; VIROLOGY;

DRUG RESISTANCE; HIV INFECTIONS; HIV PROTEASE; HIV-1; HUMANS; MUTATION; POLYMORPHISM, GENETIC; PROTEASE INHIBITORS; SAQUINAVIR; VIRUS REPLICATION;

EID: 47049115610     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318174dca6     Document Type: Article

References (37)

1. Erickson JW, Burt SK. Structural mechanisms of HIV drug resistance. Annu Rev Pharmacol Toxicol. 1996;36:545-571.
2. Velazquez-Campoy A, Muzammil S, Ohtaka H, et al. Structural and thermodynamic basis for resistance to HIV-1 protease inhibition: implications for inhibitor design. Curr Drug Targets Infect Disord. 2003;3:311-328.
3. Kagan RM, Shenderovich MD, Heseltine PNR, et al. Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir. Protein Sci. 2005;14:1870-1878.
4. King NM, Prabu-Jeyabalan M, Nalivaika EA, et al. Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J Virol. 2004; 78:12012-12021.
5. Shafer RW. Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev. 2002;15:247-277.
6. Berkhout B. HIV-1 evolution under pressure of protease inhibitors: climbing the stairs of fitness. J Biomed Sci. 1999;6:298-305.
7. Nijhuis M, Deeks S, Boucher C. Implications of antiretroviral resistance on viral fitness. Curr Opin Infect Dis. 2001;14:23-28.
8. Quiñones-Mateu ME, Aerts EJ. HIV-1 fitness: implications for drug resistance, disease progression and global epidemic evolution. In: Kuiken C, Foley B, Hahn B, et al, eds. HIV Sequence Compendium 2001. Los Alamos, NM: Los Alamos National Laboratory/Theoretical Biology and Biophysics; 2001:134-170.
9. Doyon L, Croteau G, Thibeault D, et al. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol. 1996;70:3763-3769.
10. Feher A, Weber IT, Bagossi P, et al. Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites. Eur J Biochem. 2002; 269:4114-4120.
11. Zhang YM, Imamichi H, Imamichi T, et al. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol. 1997;71:6662-6670.
12. Svicher V, Ceccherini-Silberstein F, Erba F, et al. Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors. Antimicrob Agents Chemother. 2005; 49:2015-2025.
13. Stanford University HIV Drug Resistance Database. September 1, 2007. Available at: http://hivdb.stanford.edu/cgi-bin/PRMut.cgi.
14. Van Laethem K, Schrooten Y, Dedecker S, et al. A genotypic assay for the amplification and sequencing of gag and protease from diverse human immunodeficiency virus type 1 group M subtypes. J Virol Methods. 2006; 132:181-186.
15. Snoeck J, Riva C, Steegen K, et al. Optimization of genotypic assay applicable to all human immunodeficiency virus type 1 protease and reverse transcriptase subtypes. J Virol Methods. 2005;128:47- 53.
16. Maschera B, Furfine E, Blair ED. Analysis of resistance to human immunodeficiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors. J Virol. 1995;69:5431-5436.
17. Vandamme AM, Witvrouw M, Pannecouque C, et al. Evaluating clinical isolates for their phenotypic and genotypic resistance against anti-HIV drugs. In: Kinchington D, Schinazi RF, eds. Methods in Molecular Medicine, vol. 24. Antiviral Methods and Protocols. Totowa, NJ: Humana Press Inc., 2000:223-258.
18. Weber J, Weberova J, Carobene M, et al. Use of a novel assay based on intact recombinant viruses expressing green (EGFP) or red (DsRed2) fluorescent proteins to examine the contribution of pol and env genes to overall HIV-1 replicative fitness. J Virol Methods. 2006;136:102-117.
19. Quiñones-Mateu ME, Ball SC, Marozsan AJ, et al. A dual infection/ competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression. J Virol. 2000;74:9222-9233.
20. Van Der Spoel D, Lindhal E, Hess B, et al. GROMACS: fast, flexible, and free. J Comput Chem. 2005;26:1701-1718.
21. Mammano F, Trouplin V, Zennou V, et al. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug. J Virol. 2000;74:8524-8531.
22. Baxter JD, Shapiro JM, Boucher CA, et al. Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J Virol. 2006;80:10794-10801.
23. Janini LM, Pieniazek D, Peralta JM, et al. Identification of single and dual infections with distinct subtypes of human immunodeficiency virus type 1 by using restriction fragment length polymorphism analysis. Virus Genes. 1996;13:69-81.
24. Kantor R, Fessel WJ, Zolopa AR, et al. Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapy. Antimicrob Agents Chemother. 2002;46:1086-1092.
25. Monno L, Saracino A, Scudeller L, et al. HIV-1 phenotypic susceptibility to lopinavir (LPV) and genotypic analysis in LPV/r-naive subjects with prior protease inhibitor experience. J Acquir Immune Defic Syndr. 2003; 33:439-447.
26. Rhee SY, Fessel WJ, Zolopa AR, et al. HIV-1 protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. J Infect Dis. 2005;192:456-465.
27. Rousseau CM, Birditt BA, McKay AR, et al. Large-scale amplification, cloning and sequencing of near full-length HIV-1 subtype C genomes. J Virol Methods. 2006;136:118-125.
28. Shulman NS, Zolopa AR, Passaro DJ, et al. Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic response. J Acquir Immune Defic Syndr. 2000;23:221-226.
29. Wu TD, Schiffer CA, Gonzales MJ, et al. Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J Virol. 2003;77:4836-4847.
30. Scott WRP, Schiffer CA. Curling of flap tips in HIV-1 protease as a mechanism for substrate entry and tolerance of drug resistance. Structure. 2000;8:1259-1265.
31. Matsuoka-Aizawa S, Sato H, Hachiya A, et al. Isolation and molecular characterization of a nelfinavir (NFV)-resistant human immunodeficiency virus type 1 that exhibits NFV-dependent enhancement of replication. J Virol. 2003;77:318-327.
32. Holguin A, Suñe C, Hamy F, et al. Natural polymorphisms in the protease gene modulate the replicative capacity of non-B HIV-1 variants in the absence of drug pressure. J Clin Virol. 2006;36:264-271.
33. Gonzales MJ, Machekano RM, Shafer RW. Human immunodeficiency virus type 1 reverse-transcriptase and protease subtypes: classification, amino acid mutation patterns, and prevalence in a northern California clinic-based population. J Infect Dis. 2001;184:998-1006.
34. Moody MD, Pettit SC, Shao W, et al. A side chain at position 48 of the human immunodeficiency virus type-1 protease flap provides an additional specificity determinant. Virology. 1995;207:475-485.
35. Maguire MF, Guinea R, Griffin P, et al. Changes in human immunodeficiency virus type 1 gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro. J Virol. 2002;76:7398-7406.
36. de Oliveira T, Engelbrecht S, Janse van Rensburg E, et al. Variability at human immunodeficiency virus type 1 subtype C protease cleavage sites: an indication of viral fitness? J Virol. 2003;77:9422-9430.
37. Osmanov S, Patton C, Walker N, et al. Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J Acquir Immune Defic Syndr. 2002;29:184-190.